Reich Kristian's Form 4 filing
MoonLake Immunotherapeutics (MLTX) · filed Jun 17, 2026
- Accession no.
- 0001213900-26-069753
- Filed
- Jun 17, 2026
- Trade date
- Jun 15-17, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market sales total $2.85M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Reich KristianCIK 0001920553 | Officer (Chief Scientific Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | Class A ordinary shares, par value $0.0001 per share | SSaleDisposed | −50,000 | $18.89 | −$944,500 | 2,924,551 | Indirect | |
| Jun 16, 2026 | Class A ordinary shares, par value $0.0001 per share | SSaleDisposed | −50,000 | $18.70 | −$935,000 | 2,874,551 | Indirect | |
| Jun 17, 2026 | Class A ordinary shares, par value $0.0001 per share | SSaleDisposed | −50,000 | $19.43 | −$971,500 | 2,824,551 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.